3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
431
Breast Neoplasms
300
Neoplasms
297
Colorectal Neoplasms
245
Neoplasm Metastasis
193
Ovarian Neoplasms
173
Lung Neoplasms
151
Prostatic Neoplasms
149
Recurrence
147
Pancreatic Neoplasms
143
Multiple Myeloma
134
Stomach Neoplasms
130
Squamous Cell Carcinoma of Head and Neck
128
Melanoma
123
Endometrial Neoplasms
119
Leukemia, Myeloid, Acute
114
Advanced Solid Tumors
113
Advanced Solid Tumor
111
Triple Negative Breast Neoplasms
103
Carcinoma, Hepatocellular
102
Uterine Cervical Neoplasms
90
Small Cell Lung Carcinoma
88
Lymphoma, Non-Hodgkin
84
Carcinoma, Renal Cell
72
Lymphoma, Follicular
71
Lymphoma
69
Leukemia, Lymphocytic, Chronic, B-Cell
65
Solid Tumor
64
Lymphoma, Large B-Cell, Diffuse
64
Esophageal Neoplasms
61
Interventions
Alpelisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
INDUSTRY
×
Lymphatic Abnormalities
×
Clear all
NCT05948943
2026-05-12
EPIK-L1
Novartis
Phase 2/3
Recruiting
232 enrolled